A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

Exclusion Criteria

• •Any relevant disease (other than those related to renal impairment for the renal impaired participants) within 4 weeks prior to study drug administration including infections and acute gastro-intestinal diseases (vomiting, diarrhea, constipation) requiring medical treatment
• •Acute renal failure or acute nephritis within the past 2 years
• •Febrile illness within 1 week before study drug administration
• •Malignancy diagnosed or treated within the past 5 years (hepatocellular carcinoma within the past 2 years). This does not include adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
• •Conditions associated with a risk of hypersensitivity reactions as judged by the investigator
• •Any participant not able to produce urine and/or needing dialysis
• •Dialysis for acute renal failure within the previous 6 months prior to administration of study intervention
• •Contrast agent administration within one month prior to screening or during the screening period
• •Indication for immunosuppressants, receiving cytotoxic therapy, immunosuppressive therapy, or other immunotherapy within 6 months prior to administration of study intervention
• •Clinically relevant abnormalities in physical examination, ECG, clinical chemistry, hematology, or urinalysis as judged by the investigator
• •Heart rate below 45 bpm or above 110 bpm
• •Systolic blood pressure below 90 mmHg or above 170 mmHg
• •Diastolic blood pressure below 45 or above 105 mmHg
• •Indication or evidence for long QT syndrome for all participants; additionally for participants with normal renal function: QT interval corrected using Fridericia's method (QTcF) \> 470 msec
• •History of COVID-19 within 6 months prior to screening
• •Long COVID-19 syndrome or other clinically relevant COVID-19-related symptoms or sequela
• •Incomplete SARS-CoV-2 vaccination
• •Vaccination planned before completion of the last study visit